Withdrawals due to adverse events · Patients with active mild to moderate ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · active EoE patients
1 finding from 1 review
Withdrawals due to adverse events · active EoE pediatric patients
It is very uncertain whether one‐food elimination diet changes withdrawals due to adverse events compared with six‐food elimination diet (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with inflammatory bowel disease
It is very uncertain whether any‐treatment‐dose vitamin D (greater than 400 IU/day) changes withdrawals due to adverse events compared with supplemental‐dose vitamin D (less than 400 IU/day) (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with inflammatory bowel disease
It is very uncertain whether vitamin D (all doses) changes withdrawals due to adverse events compared with placebo/no treatment (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with inflammatory bowel disease
It is very uncertain whether high‐treatment‐dose vitamin D (greater than 1000 IU/day) changes withdrawals due to adverse events compared with low‐treatment‐dose vitamin D (400 IU/day to 1000 IU/day) (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active Crohn's disease
Infliximab 5 mg/kg showed no clear difference in withdrawals due to adverse events compared with purine analogues (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active Crohn's disease
The review found no eligible studies for this question.
2 findings from 1 review
Withdrawals due to adverse events · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · Patients with active Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · Patients with active Crohn's disease
Infliximab 5 mg/kg showed no clear difference in withdrawals due to adverse events compared with CT‐P13 biosimilar 5 mg/kg (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active Crohn's disease
The review found no eligible studies for this question.
2 findings from 1 review
Withdrawals due to adverse events · children (4 to 18 years) with functional abdominal pain disorders
It is very uncertain whether synbiotic changes withdrawals due to adverse events compared with placebo (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · children (4 to 18 years) with functional abdominal pain disorders
It is very uncertain whether probiotic changes withdrawals due to adverse events compared with placebo (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · children with Hirschsprung's disease (HD)
1 finding from 1 review
Withdrawals due to adverse events · people with active UC
1 finding from 1 review
Withdrawals due to adverse events · people with active UC
1 finding from 1 review
Withdrawals due to adverse events · Patients with quiescent ulcerative colitis
1 finding from 1 review
Withdrawals due to adverse events · of active and inactive people with ulcerative colitis
1 finding from 1 review
Withdrawals due to adverse events · people with active UC
Antibiotics showed no clear difference in withdrawals due to adverse events compared with placebo (low certainty).
1 finding from 1 review